Capstone Therapeutics Corp., of Tempe, Ariz., and Lipimetix Development Inc., Capstone's 60 percent-owned joint venture (JV), said its lenders informed the companies they would not exercise their option to extend the exclusive due diligence period through March 31, by loaning Capstone a second $1 million, under the terms of the previously reported securities purchase agreement.